Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

Ítems similars

• Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
  per: Ibrahim, Amr R., et al.
  Publicat: (2011)
• Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response
  per: Kuwabara, Aya, et al.
  Publicat: (2010)
• European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
  per: Marin, David, et al.
  Publicat: (2008)
• Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
  per: Ibrahim, Amr R., et al.
  Publicat: (2010)
• Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
  per: Nteliopoulos, Georgios, et al.
  Publicat: (2019)